NEONATAL RESPIRATORY TRIALS IN SICK & PRETERM NEWBORN INFANTS
Professor Brett J. Manley, Consultant Neonatologist
Mercy Hospital For Women, Melbourne & Professor of Neonatal Medicine, Department of Obstetrics, Gynaecology and Newborn Health, University of Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | August 2025
Professor Brett J. Manley is a Consultant Neonatologist at the Mercy Hospital for Women in Melbourne, Australia, and a Professor of Neonatology in the Department of Obstetrics, Gynaecology and Newborn Health at The University of Melbourne. His research is supported by a fellowship from the National Health and Medical Research Council (NHMRC), Australia.
He divides his work time between being a clinician in the neonatal intensive care unit (NICU), and a clinical researcher. He is passionate about caring for sick and preterm newborn infants and contributing to the evidence base for their care, to improve their shorter- and longer-term outcomes.
Prof Manley leads and collaborates on large national and international randomised clinical trials in neonatology. He previously collaborated on 4 randomised trials of nasal high-flow as non-invasive respiratory support for preterm and term infants, all of which were published in N Engl J Med. Recently he led the PLUSS trial of intratracheal budesonide for extremely preterm infants, that recruited in 21 NICUs across 4 countries, the results of which were published in JAMA. PLUSS was awarded the Australian Clinical Trials Alliance Trial of the Year in 2025. Another passion of his is mentoring and supervising early career researchers to undertake their own clinical trials.
Source: Supplied
https://orcid.org/0000-0003-0212-7956
-
Dr Zarina Greenberg
RESEARCH IN SANFILIPPO
@ SAHMRI
ADELAIDE, SOUTH AUSTRALIA, AUSTRALIA -
At the frontier of human cellular neuroscience research
Associate Professor Cedric Bardy is the Director of The Laboratory for Human Neurophysiology, Genetics & Stem Cells, located at SAHMRI. South Australia.
His current research uses preclinical, patient-derived cell models to test innovative therapeutic strategies, with a current focus on Parkinson’s disease, brain cancer and childhood dementia (Sanfilippo syndrome).
His work has established a platform to facilitate the discovery and validation of treatments for brain disorders. Their research is at the frontier of human cellular neuroscience research and translational applications that benefit global public health.
-
CASE STUDY Role of Exercise in Metabolic Associated Fatty Liver Disease
Dr. Shelley Keating AES AEP* is an Accredited Exercise Physiologist, a researcher, and a senior lecturer at the School of Human Movement and Nutrition Sciences at the University of Queensland in Brisbane, Australia. Dr. Keating’s research primarily focuses on the role of exercise in the management of metabolic dysfunction associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease. MASLD affects a significant portion of the global adult population, with many individuals unaware of their condition.
